Monday, 10 Dec 2018

Biologic/Novel Rx

Datesort ascending Type Title Save
28 Aug 2018 News Questions Remain about Shingrix Safety in Rheumatic Disease
13 Aug 2018 News Success of Stopping Depends on the Biologic
06 Aug 2018 Social Psoriasis biologic pipeline continues to grow. In development are IL-23 inhibitors (risankizumab, mirikizumab) & the IL-17 A/F inhbitor (bimekizumab). Tildrakizumab and certolizumab were approved for Psoriasis earlier in 2018. https://t.co/QFbdtO1Lua
04 Aug 2018 Social Switching to biosimilars (and generics) saved the UK National Health Service NHS England saved £324 million in 2017/2018. https://t.co/WxpWYAt3bh
02 Aug 2018 Social Pfizers announces EU approval for tofacitinib 10 mg bid for use in adults with moderately to severely active ulcerative colitis (UC) who have had an inadequate response or intolerance to DMARD or biologic agents https://t.co/Cw9JFozphJ
01 Aug 2018 Social Positive Results from Phase III study of RHB-104 in Crohn’s Disease; RHB-104 is a combo antimycobacterial-antibiotic with antiinflammatory properties (given w/ hypothesis that CD caused by a mycobacterium avium paratuberculosis https://t.co/w78xCKkAlG
01 Aug 2018 News IL-1 Suppression May Improve Dilated Cardiomyopathy
31 Jul 2018 Social EMA's CHMP has recommended approval of the IL-23 inhibitor tildrakizumab (Ilumetri, Almirall) for adults with moderate - severe plaque psoriasis. (Based on reSURFACE1 and reSURFACE2 RCTs w/ >80% PASI 75 responses. https://t.co/Qm0qIgAJ2G
20 Jul 2018 Social RT @AngusWorthing: FDA releases #biosimilars action plan. @ACRheum through AMA has pushed FDA to finalize interchangeability pathway. Fing…
14 Jul 2018 Social RheumNow coverage of Biologic use and switching from the BSRBR database https://t.co/j3rAiFjjWh https://t.co/jIFSBEnvzc
12 Jul 2018 Social RT @ByJonGardner: Some interesting insight on why US biosimilar uptake has been so anaemic from a Leerink note. Main reasons: PBMS lose mon…
12 Jul 2018 News Defining Refractory RA by Biologic Use
11 Jul 2018 News IL-23 Inhibitor Fails in Ankylosing Spondylitis
10 Jul 2018 Blog Prescription Drugs and the Effect on Access to Biosimilars in the US
09 Jul 2018 Social RT @SGottliebFDA: For this week’s #FDA #SUNDAYTWEETORIAL, I want to talk about #biosimilars. It's a critical moment in the development of t…
26 Jun 2018 News Five Barriers to Biosimilar Adoption in the US
25 Jun 2018 Social RheumNow Week in Review is up! Cush reviews lack of DMOADs, EULAR18, Penicillamine cost, ANCA+ Infections , NSAIDs in Pregnancy and Seropostive vs. Seronegative Outcomes. https://t.co/dFJ23wziBQ or do the podcast on iTunes or here>> https://t.co/yo78vSMQRQ
25 Jun 2018 Social Uncontrolled, off-label reports of Tofacitinib 10 mg bid in patients with refractory dermatomyositis - promising but more clinical trial data needed! https://t.co/vCgC0scAa9
20 Jun 2018 ACR Video Dr. Olga Petryna at EULAR 2018 - Biologics Don't Effect Infection Rates with Arthroplasty
18 Jun 2018 News EULAR 2018 - Day 4 Report